Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:10:30.739Z.
Calculation as of: 2026-10-06T14:10:30.739Z.
Quote observation: 2026-10-06T14:10:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0
PEG RATIO
N/A
Acumen Pharmaceuticals, Inc.
Market Cap
$148.07M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $148.07M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.95M | N/A |
| Immuneering Corporation (IMRX)vs › | $145.39M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $153.56M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $141.70M | N/A |
| Codexis, Inc. (CDXS)vs › | $152.74M | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $139.95M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $155.62M | N/A |
| Alpha Cognition Inc (ACOG)vs › | $140.09M | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
